Iran Bans U.S., U.K. Covid-19 Vaccines in Feud With West
(Bloomberg) -- Iran's Supreme Leader said he was banning the purchase of coronavirus vaccines made by U.S. and U.K. companies, limiting the country's options as it confronts the worst outbreak in the Middle East.
“The import of American and British vaccines to the country is banned,” Ayatollah Ali Khamenei said in a televised speech Friday. “If their Pfizer manufacturer can produce a vaccine, then why do they want to give it to us?” he said. “They should use it themselves so they don't experience so many fatalities. Same with the U.K.”
Khamenei is a strident critic of the U.S., which under President Donald Trump left the 2015 nuclear deal that had offered Iran a route to economic recovery and reimposed sweeping sanctions. Iranian officials have said the penalties hindered the country's response to the pandemic.
The cleric said western drug companies tested vaccines on other countries “to see if they work or not.”
Khamenei only singled out Pfizer Inc. by name, but the ban would appear to rule out imports of vaccines made by U.K.-based AstraZeneca Plc, as well as U.S. firm Moderna Inc.
Iran's Red Crescent Society later announced the cancellation of an existing deal for 150,000 shots of the Pfizer-BioNTech vaccine donated by U.S. philanthropists, the semi-official Tasnim news agency reported, citing an interview with spokesman Mohammad-Hassan Qosian-Moqaddam.
He said the Pfizer order had been “provisional,” and that the Red Crescent would receive “one million coronavirus vaccines from one of the eastern countries,” most likely Russia, China or India.
Central bank Governor Abdolnaser Hemmati said in December that Tehran was in talks with China for a million vaccine doses. Officials have also held discussions with Russia about joint production of its Sputnik V jab.
Hemmati had also said Iran hoped to purchase of 16.8 million vaccine doses from the World Health Organization's COVAX facility, after overcoming some of the obstacles created by U.S. sanctions.
Iran, which has recorded more than 1.2 million cases of Covid-19 and in excess of 55,000 fatalities from the virus, also aims to have a locally developed vaccine available by the summer.
©2021 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.